Loading…
← CockpitCompetitor Analysis › 445680.KS Curiox Biosystems Co., Ltd.Open in the cockpit ↗

Curiox Biosystems Co., Ltd.445680.KSCompetitor analysis, valuation and peers

South Korea · KRW·Information Technology›Packaged Software
Momentum neutral 45
Mkt cap
$551M
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$7.17M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-37.8 pp
WACC 8.0%
Hurdle
n/a
no reverse DCF
Close · KRW₩45,700
1D+2.4%
1W-21.1%
1M-15.4%
3M-9.7%
6M-51.8%
YTD-60.9%
1Y-38.8%
ATR %13.7%
52w lowhigh69.4% off high

What Curiox Biosystems does

Employees: 22

Curiox Biosystems at a glance

Size Curiox Biosystems (445680.KS) is a South Korea Information Technology company (Packaged Software) with a market value of $551M, the 326th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩45,700 on 18 Nov 2026.

Performance Over six months the shares fell 51.8%, against -11.4% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 37.2% over the last twelve months (peer median -3.0%); the operating margin is -244.1% (peer median -4.9%).

Valuation It trades at 124.3× enterprise value to sales against a peer median of 3.7× (most expensive of 19).

Capital Return on invested capital runs 37.8 points below its cost of capital (8.0% WACC).

Relative performance

507510021 May 202621 Aug 202618 Nov 2026Peer median 88445680.KS 50
Six months, rebased to 100: Curiox Biosystems against the median of its 20 peers (local-currency closes).

Curiox Biosystems financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩5.84B₩5.15B₩4.59B₩6.79B₩7.24B
Revenue growth—+12%-32%-6%—
Gross profit₩998M₩401M₩783M₩2.20B₩3.31B
EBITDA-₩12.1B-₩10.1B-₩11.3B-₩8.61B-₩9.82B
Net income-₩15.1B-₩27.2B-₩8.09B-₩10.0B-₩11.5B
Free cash flow-₩10.6B-₩11.2B-₩9.96B-₩8.38B-₩10.8B
Capital expenditure₩64.1M₩136M₩258M₩212M₩841M
Total debt₩517M₩2.45B₩8.14B₩965M₩387M

Quarterly statements and history in the cockpit →

Curiox Biosystems competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%3632301556IIIV002425GNSSTYLNEXNHQ688023603869688207989068848930038075953005716002123993300996300550445680.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Curiox Biosystems is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%0×50×100×3632301556IIIVGNS6882073993445680.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Curiox Biosystems is the large dot.

Curiox Biosystems competitors and peer comparison

How Curiox Biosystems compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Curiox Biosystems against its 20 peers (data as of 18 Nov 2026)
Measure445680.KSPeer medianRank in peer set
1-month return-15.4%-8.6%7th lowest of 21
6-month return-51.8%-11.4%2nd lowest of 21
Distance from 52-week high-69.4%-36.0%3rd lowest of 21
Revenue growth (TTM)+37.2%-3.0%3rd highest of 20
Operating margin-244.1%-4.9%lowest of 20
EV / Sales124.3×3.7×most expensive of 19
ROIC minus cost of capital-37.8 pp-7.6 pp2nd lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Curiox Biosystems 445680.KSSouth Korea$551M-52%+37%-244%124.3×n/an/a
GREE Holdings.Inc 3632.TJapan$551M+23%-11%8%0.7×-10.4%-2.0%
Zhejiang TOP Cloud-agri Technology 301556.SZChina$551M-40%-14%13%6.7×28.0%+14.0%
i3 Verticals IIIVUnited States$553M+7%-6%2%3.6×n/an/a
Kaiser (China) Culture 002425.SZChina$554M+22%-3%-53%6.9×n/an/a
Niewiadow Polish Military Group Joint Stock GNS.WAPoland$547M-6%+490%-73%23.9×n/an/a
Seshaasai Technologies STYL.NSIndia$545M+17%-2%23%3.1×11.9%+7.9%
Nexxen International NEXNUnited States$545M+17%+4%6%1.1×4.6%+11.5%
Horizon Quantum HQUnited States$544M-11%n/an/an/an/an/a
DBAPPSecurity 688023.SSChina$563M-16%+2%-5%1.6×2.9%+10.3%
ENC Digital Technology 603869.SSChina$538M-34%-10%-8%3.9×n/an/a
Beijing Deep Glint Technology 688207.SSChina$564M-11%-14%-195%22.3×n/an/a
Tanwan 9890.HKHong Kong$567M-40%-4%-6%n/an/an/a
Sansec Technology 688489.SSChina$535M-23%+18%-7%4.9×n/an/a
Shanghai Amarsoft Information & Technology 300380.SZChina$569M-33%-2%4%3.4×n/an/a
Argo Graphics 7595.TJapan$533M-8%+8%15%0.8×-9.9%+10.5%
Hangzhou Anysoft Information Technology 300571.SZChina$533M-58%+17%-11%4.9×n/an/a
Gresgying Digital Energy Technology 600212.SSChina$533M-40%-8%-6%3.0×21.6%+38.2%
PKSHA Technology 3993.TJapan$570M+1%+78%16%2.1×12.8%+34.7%
Pansoft 300996.SZChina$575M-22%-4%11%4.3×n/an/a
Heren Health 300550.SZChina$528M-2%-4%-11%8.1×44.0%-0.9%

Questions

Which companies are Curiox Biosystems's closest peers?
The cockpit's peer set: GREE Holdings.Inc (3632.T), Zhejiang TOP Cloud-agri Technology (301556.SZ), i3 Verticals (IIIV), Kaiser (China) Culture (002425.SZ), Niewiadow Polish Military Group Joint Stock (GNS.WA), Seshaasai Technologies (STYL.NS), Nexxen International (NEXN), Horizon Quantum (HQ).
Is Curiox Biosystems expensive compared with its peers?
On ev / sales it trades at 124.3× against a peer median of 3.7×, most expensive of 19 in its peer set.
How has Curiox Biosystems stock performed?
Over six months to 18 Nov 2026 the shares returned -51.8% against -11.4% for the median peer; over one year -38.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.